On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous coronary intervention (PCI). Read more.
FDA approves antiplatelet drug for use during PCI
Most Recent Content
For Nurse Practitioners
Will Omicron Be More Contagious Than Delta?
If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...
